Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis

Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis

IntroductionVarious immunosuppressive regimens have been developed for the treatment of lupus nephritis (LN). This study aimed to compare the efficacy and safety of immunosuppressive regimens in adults with LN.MethodsWe systematically searched the PubMed, Embase, and Cochrane Central Register of Con...

Full description

Bibliographic Details
Main Authors:	Nan Jiang, Shangyi Jin, Chen Yu, Jiuliang Zhao, Qian Wang, Xinping Tian, Mengtao Li, Xiaofeng Zeng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-10-01
Series:	Frontiers in Immunology
Subjects:	lupus nephritis immunosuppressive efficacy safety network meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1232244/full

Similar Items

New insights into the pathogenesis and management of rheumatoid arthritis
by: Shangyi Jin, et al.
Published: (2022-12-01)

Interpretation on the 2022 Chinese Guideline for the Management of Pregnancy and Reproduction in Patients with Systemic Lupus Erythematous
by: TIAN Xinping, et al.
Published: (2023-05-01)

LP-188 Glucocorticoids withdrawn in systemic lupus erythematosus patients with serologically active clinically quiescent state: a desirable goal
by: Xiaofeng Zeng, et al.
Published: (2023-07-01)

LSO-009 The impact of high-risk antiphospholipid antibodies profile on major organ damage progression in systemic lupus erythematosus: CSTAR multiple prospective cohort study
by: Xiaofeng Zeng, et al.
Published: (2023-07-01)

Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population
by: Chaojun Hu, et al.
Published: (2020-10-01)

Risk factors for incidence of interstitial lung disease in patients with rheumatoid arthritis: a systematic review and meta-analysis
by: Xiaofeng Zeng, et al.
Published: (2024-11-01)

Predictive Factors for the Common Adverse Maternal and Fetal Outcomes in Pregnancies Complicated by Systemic Lupus Erythematosus
by: Qianwen Dai, et al.
Published: (2024-05-01)

Finding Possible Solutions for the Management of Systemic Lupus Erythematosus from the Current Situation and Challenges in China
by: TIAN Xinping, et al.
Published: (2022-03-01)

The prognosis and management of reclassified systemic lupus erythematosus associated pulmonary arterial hypertension according to 2022 ESC/ERS guidelines
by: Yutong Li, et al.
Published: (2024-05-01)

Risk prediction of new-onset thrombocytopenia in patients with systemic lupus erythematosus: a multicenter prospective cohort study based on Chinese SLE treatment and research group (CSTAR) registry
by: Yupei Zhang, et al.
Published: (2024-12-01)

Extra-criteria clinical manifestations of antiphospholipid antibody should not be ignored
by: Can Huang, et al.
Published: (2022-09-01)

Treatment of refractory lupus nephritis using leflunomide: A prospective study
by: Shuo Zhang, et al.
Published: (2023-03-01)

Identification of Lupus-Associated Genes in the Pathogenesis of Pre-eclampsia Via Bioinformatic Analysis
by: Qianwen Dai, et al.
Published: (2024-08-01)

LSO-073 Improvements and challenges of systemic lupus erythematosus associated pulmonary arterial hypertension: a 10-year multicenter cohort study
by: Xiaofeng Zeng, et al.
Published: (2023-07-01)

Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review
by: Xiaofeng Zeng, et al.
Published: (2022-09-01)

The diagnostic and prognostic value of growth differentiation factor‐15 in systemic lupus erythematosus‐associated pulmonary arterial hypertension
by: Junyan Qian, et al.
Published: (2023-01-01)

Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes
by: Can Huang, et al.
Published: (2025-01-01)

Belimumab in early systemic lupus erythematosus: A propensity score matching analysis
by: Chaofan Lu, et al.
Published: (2024-08-01)

The clinical characteristics of Chinese Takayasu’s arteritis patients: a retrospective study of 411 patients over 24 years
by: Jing Li, et al.
Published: (2017-05-01)

Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study
by: Wanting Qi, et al.
Published: (2022-06-01)

Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients
by: Siting Li, et al.
Published: (2023-04-01)

Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis
by: Liying Peng, et al.
Published: (2020-09-01)

Programmed Cell Death Pathways in the Pathogenesis of Idiopathic Inflammatory Myopathies
by: Jia Shi, et al.
Published: (2021-11-01)

Rheumatoid meningitis: a rare neurological complication of rheumatoid arthritis
by: Siyuan Fan, et al.
Published: (2023-06-01)

Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study
by: Jun Li, et al.
Published: (2024-03-01)

Serum Calprotectin as a Potential Predictor of Microvascular Manifestations in Patients with Antiphospholipid Syndrome
by: Yuan Zhao, et al.
Published: (2023-10-01)

Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort
by: Xiaofeng Zeng, et al.
Published: (2023-07-01)

Association between acute phase reactants, interleukin-6, tumor necrosis factor-α, and disease activity in Takayasu’s arteritis patients
by: Jing Li, et al.
Published: (2020-12-01)

LP-038 Infection in systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a potential key to improve outcomes
by: Wei Bai, et al.
Published: (2023-07-01)

Factors Associated With Renal Involvement in Primary Sjögren's Syndrome: A Meta-Analysis
by: Ruping Hong, et al.
Published: (2020-11-01)

Immune Thrombocytopenia Could be an Independent Clinical Phenotype of Antiphospholipid Syndrome: A Prospective Cohort Study
by: Yu Shi, et al.
Published: (2023-02-01)

Systemic lupus erythematosus related thrombotic microangiopathy: A retrospective study based on Chinese SLE Treatment and Research Group (CSTAR) registry
by: Yupei Zhang, et al.
Published: (2025-03-01)

Anti-β2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China
by: Xiaofeng Zeng, et al.
Published: (2023-11-01)

Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort
by: Chaojun Hu, et al.
Published: (2021-09-01)

LO-035 The effects and molecular mechanisms of TRAF5 on pulmonary artery endothelial cells in patients with systemic lupus erythematosus associated pulmonary arterial hypertension
by: Xiaofeng Zeng, et al.
Published: (2023-07-01)

Clinical Characteristics of Systemic Lupus Erythematosus with Cirrhosis
by: Hanxiao You, et al.
Published: (2020-01-01)

Dancing with disorder: chorea – an unusual and neglected manifestation of antiphospholipid syndrome
by: Xiaofeng Zeng, et al.
Published: (2024-10-01)

Clinical efficacy of tacrolimus in systemic lupus erythematosus with various manifestations: a real-world study
by: Wei Bai, et al.
Published: (2022-09-01)

Interpretation on the Chinese Guideline for the Diagnosis and Treatment of Takayasu's Arteritis (2023)
by: JIN Shangyi, et al.
Published: (2024-05-01)

Chronic abdominal aortic occlusive disease related to antiphospholipid syndrome: a rare presentation
by: Wei Liu, et al.
Published: (2024-02-01)